Sarcoma  >>  Iclusig (ponatinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iclusig (ponatinib) / Takeda, Otsuka
NCT01874665: A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Checkmark For GIST at ASCO 2015
May 2015 - May 2015: For GIST at ASCO 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ESMO 2014
More
Completed
2
45
US
Ponatinib, AP24534, Iclusig
Ariad Pharmaceuticals
GIST
02/15
07/16
POETIG, NCT03171389 / 2015-002285-23: Trial - POnatinib After rEsisTance to Imatinib in GIST

Unknown status
2
81
Europe
Ponatinib 30 MG, Iclusiq
Sebastian Bauer, Hannover Medical School, Helios Klinikum Berlin-Buch, University Hospital Tuebingen, Universitätsmedizin Mannheim, University Hospital, Aachen, Helios Klinikum Bad Saarow, WiSP GmbH
GIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation
09/18
09/20

Download Options